H. Haldun EMİROĞLU, Rejin KEBUDİ, İnci AYAN, Nezahat GÜRLER, Ömer GÖRGÜN, Bülent ZÜLFİKAR, Melike KESER, Nevin HATİPOĞLU, Ayper SOMER, Nuran SALMAN

Vankomisine dirençli enterokok bakteriyemisi olan kanserli bir çocukda linezolid tedavisi

Nozokomiyal infeksiyonların % 10-12’sinden enterokoklar sorumludur. Vankomisine dirençli enterokoklar ile kolonizasyon, genellikle yoğun bakım veya onkoloji ünitelerinde uzun süre kalan hastalarda görülmektedir. Bir hastadan diğerine sağlık personeli ile geçebilmektedir. Düşkün hastalarda kolonizasyonun ardından infeksiyon gelişme sıklığı yüksektir. Vankomisine dirençli enterokokların neden olduğu infeksiyonların tedavisinde linezolid değerli bir ilaçtır. Burada İstanbul Üniversitesi Onkoloji Enstitüsü Pedatrik Hematoloji-Onkoloji Bilim Dalı’nda nöroblastomlu bir olguda ilk kez saptanan ve linezolidle başarılı bir şekilde tedavi edilen vankomisine dirençli enterokok bakteriyemisi olgusu sunulmuştur.

Anahtar Kelimeler:

İlaç direnci, bakteriyel, Vankomisin, Enterococcus, Bakteriyemi, Süt çocuğu, Kadın, Nöroblastom, Çapraz enfeksiyon

The use of linezolid in the treatment of vancomycin-resistant enterococcal bacteremia in a child patient with cancer

Enterococci are responsible for 10-12 % of nosocomial infections. Colonization is usually acquired by susceptible hosts in intensive care units or oncology units for prolonged periods with a high rate of patient colonization with vancomycin-resistant enterococci. It can be transmissed from one patient to another by health care workers. Immunocompromised patients have an increased likelihood of developing infection following colonization. Linezolid is an anti-infective agent that has recently become available to treat infections caused by vancomycin-resistant enterococci. We describe the first confirmed case of bacteremia with vancomycin-resistant enterococci in Istanbul University Oncology Institute Pediatric Hematology - Oncology Division, in a patient with neuroblastoma who was successfully treated with linezolid.

Keywords:

Drug Resistance, Bacterial, Vancomycin, Enterococcus, Bacteremia, Infant, Female, Neuroblastoma, Cross Infection,

PDF

___

1. Al-Tatari H, Abdel-Haq N, Chearskul P, Asmar B: Antibiotics for treatment of resistant gram-positive coccal infections, Indian J Pediatr 2006;73(4):323-34.
2. Atkins JL, Hidvegi N, Teare L, Dziewulski P: The use of linezolid in the treatment of vancomycinresistant enterococcal septicaemia in two patients with burn injuries, Burns 2002;28(2):185-8.
3. Bain KT, Wittbrodt ET: Linezolid for the treatment of resistant gram-positive cocci, Ann Pharmacother 2001;35(5):566-75.
4. Batts DH: Linezolid-a new option for treating gram-positive infections, Oncology 2000;8(Suppl 6):23-9.
5. Bradley SJ: Control of glycopeptide-resistant enterococci in an oncology unit, Pharmacotherapy 2000;20(9):S203-12.
6. French G: Linezolid, Int J Clin Pract 2001;55(1):59-63.
7. Fung HB, Kirschenbaum HL, Ojofeitimi BO: Linezolid: an oxazolidinone antimicrobial agent, Clin Ther 2001;23(3):356-91.
8. Perry CM, Jarvis B: Linezolid: a review of its use in the management of serious gram-positive infections, Drugs 2001;61(4):525-51.
9. Zirakzadeh A, Patel R: Vancomycin-resistant enterococci: colonization, infection, detection, and treatment, Mayo Clin Proc 2006;81(4):529-36.
10. Zubaidah AW, Ariza A, Azmi S: Hospital-acquired vancomycin-resistant enterococci: now appearing in Kuala Lumpur Hospital, Med J Malaysia 2006;61(4):487-9.